YZYan-Pei Zhang

Yan-Pei Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yan-Pei Zhang has a total of 52 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Restoration of CD8+ T cell stress resilience and abscopal effect of radioimmunotherapy via SFRP2-WNT-HSF1 pathway targeting

    by Yu-Jie Zeng, Kui-Mao Zhuang, Pei-Shuang Xu, Min-Jie Ruan, Le-Yi Lin, Ze-Qin Guo, Zi-Xuan Rong, Zhao-Guo Liu, Zhong-Yi Dong, Yan-Pei Zhang

    Background The abscopal effect, in which radiotherapy of one tumor is associated with regression of distant non-irradiated tumors, remains uncommon even when combined with immune checkpoint blockade. Although systemic T cell priming is required, the mechanisms that determine whether effector T cells persist within distant tumors remain unclear. We investigated whether SFRP2-expressing stromal cells limit CD8+ T cell stress resilience in abscopal tumors. Methods We used bilateral mouse tumor models treated with fractionated radiotherapy plus anti-PD-1 antibody, combined with immune profiling of irradiated tumors, tumor-draining lymph nodes, and distant tumors. Human lung cancer specimens, public transcriptomic datasets, fibroblast-specific Sfrp2 deletion, single-cell RNA sequencing, immunostaining, flow cytometry, and fibroblast-T cell co-culture assays were used to examine the relationship between SFRP2, CD8+ T cell apoptosis, and stress-response signaling. Statistical analyses included two-sided tests and multiple-comparison correction where appropriate. Results Here we show that radioimmunotherapy activates local tumor immunity and tumor-draining lymph node priming, but resistant distant tumors fail to maintain CD8+ T cell accumulation. SFRP2 is enriched in fibroblast-like stromal compartments and is inversely associated with CD8+ T cell infiltration. Fibroblast-specific Sfrp2 deletion reduces CD8+ T cell apoptosis and restores an HSPA1A/HSP70-associated stress-resilience program. Mechanistically, SFRP2 suppresses a WNT-HSF1-HSPA1A signaling program, whereas Hspa1a overexpression reduces SFRP2-associated caspase-3 activation in T cells. Conclusions These findings identify stromal suppression of CD8+ T cell stress resilience as a mechanism of abscopal resistance and support SFRP2-WNT-HSF1 pathway targeting as a potential strategy to improve radioimmunotherapy.

  • CRTAM inhibition mitigates toxicity of immune checkpoint inhibitors without antitumor efficacy trade-off

    by Si-Cong Ma, Zi-Xuan Rong, Zi-Peng Xu, Yan-Pei Zhang, Kui-Mao Zhuang, Hao Sun, Chuan-Hui Cao, Ze-Nan Wu, Hai-Peng Zhang, Qiang Zuo, et al.

    The benefit from immune checkpoint blockade (ICB) can be mitigated by the onset of immune-related adverse events (irAEs). The identification of checkpoints specific to irAEs could mitigate toxicity without antitumor efficacy trade-off. Here we integrated transcriptome and pharmacovigilance data to decipher the efficacy–toxicity equilibrium of ICB-regulated molecules and identified cytotoxic and regulatory T cell molecule (CRTAM) as an irAE checkpoint. Crtam knockout or T cell lineage-specific Crtam ablation impaired irAE induction in preclinical models. CRTAM⁺ T cells preferentially infiltrated normal tissues over tumors through the CRTAM–cell adhesion molecule 1 interaction and promoted interleukin 23-centered type 3 immunity. CRTAM inhibition preserved the ‘hot’ tumor microenvironment required for efficacy while mitigating toxicity in tumor-bearing irAE models. Quantification of the CRTAM–type 3 immune axis in blood samples enabled monitoring of irAEs in cohorts treated with ICB. Our study identifies CRTAM as a T cell checkpoint of irAEs, providing a potential target to uncouple efficacy from toxicity during immunotherapy.


  • Open Access

    Figure S3 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer

    by Li-Li Long, Si-Cong Ma, Ze-Qin Guo, Yan-Pei Zhang, Zhenzhen Fan, Li-Juan Liu, Li Liu, Duan-Duan Han, Meng-Xin Leng, Jian Wang, et al.

    Overexpression of mutant PARP1 promotes activation of the IFNγ signaling pathway. (a, b) A549 lung cancer cells and LLC1 lung cancer cells were transfected with the catalytic mutant Flag-PARP1 (E988) followed by stimulation with IFNγ. The lysates were then subjected to western blot analysis for indicated proteins.

  • Open Access

    Figure S6 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer

    by Li-Li Long, Si-Cong Ma, Ze-Qin Guo, Yan-Pei Zhang, Zhenzhen Fan, Li-Juan Liu, Li Liu, Duan-Duan Han, Meng-Xin Leng, Jian Wang, et al.

    Anti-PD-1/olaparib treatment promotes IFNγ secretion by CD8+ T cells in the tumor microenvironment. Mice-bearing orthotopic lung tumors were treated with different therapies. Representative IHC stainings of IFNγ expression in tumor tissues were shown. Scale bar, 50 μm.The right graph showed the IHC statistical analysis of IFNγ expression in tumor tissues. n = 5 fields from independent tumors. Data are represented as mean ± SD; Student's t-tests; **P<0.01; ***P<0.001; ****P<0.0001; ns, not significant.

  • Open Access

    Figure S7 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer

    by Li-Li Long, Si-Cong Ma, Ze-Qin Guo, Yan-Pei Zhang, Zhenzhen Fan, Li-Juan Liu, Li Liu, Duan-Duan Han, Meng-Xin Leng, Jian Wang, et al.

    Olaparib promoted STING activation in LKB1-mutant/loss NSCLC cells and LLC-derived tumors. (a) Cells were pre-treated with olaparib (5 μM) for 6 hours and then stimulated with IFNγ for 24 hours. The cell lysates were then subjected to western blot analysis for key proteins in the STING signaling pathway. (b) Representative IHC staining of STING and pSTING in LLC-LV-Lkb1 tumors and LLC-LV-Ctrl tumors following different treatments. Scale bar: 200 μm. (c) IHC statistical analysis of STING and pSTING expression in LLC-LV-Ctrl/Lkb1 tumors following indicated treatment. n=5 fields from independent tumors. Data are represented as mean ± SD; Student's t-tests; ***P<0.001; ****P<0.0001; ns, not significant.

  • Open Access

    Figure S1 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer

    by Li-Li Long, Si-Cong Ma, Ze-Qin Guo, Yan-Pei Zhang, Zhenzhen Fan, Li-Juan Liu, Li Liu, Duan-Duan Han, Meng-Xin Leng, Jian Wang, et al.

    LKB1 deficiency impairs IFNγ pathway by hindering STAT1 phosphorylation. (a) Western blotting for detection of LKB1 and pAMPK expression in K and KL lung tumors. (b) UMAP of sub-clustered CD45+ immune cells from lung tumor samples of K and KL, colored by cell types. (c) The proportion of each immune cell type in K vs KL. (d) UMAP of sub-clustered cells from lung tumor samples of KP and KPL mice, colored by their 10 major cell types. (e) Gene set enrichment analysis (GSEA) showing downregulated response to interferon-gamma in KPL compared with KP. (f) A549 lung cancer cells were transfected with lentivirus expressing the indicated genes (LV-Ctrl, LV-LKB1-WT, and LV-LKB1-Mut) followed by stimulation with IFNγ. The expression of LKB1 and pAMPK was analyzed by western blotting. (g) Expression of pSTAT1 was measured by immunofluorescent staining in the three groups of A549 cells treated with IFNγ for 24 hours. Nuclei were visualized with DAPI (blue). Scale bar = 100 μm. (h) Immunoblot of the indicated IFNγ-induced proteins in different lung cancer cells. (i) Decreased IFNγ signaling downstream molecules, PD-L1, and chemokines, in KPL vs KP malignant cells. (j) PD-L1 transcription and chemokine signature score in tumor cells of K vs KL. (k) Western blot illustrating LKB1 expression in LLC1 and CMT-167 cells respectively. (l, m) Lewis lung cancer cells (LLC1) were transfected with shRNA specific for Lkb1 (shLkb1) or noneffective scrambled shRNA (shCtrl) followed by treatment with IFNγ for 24 hours. Western blotting for the detection of pSTAT1, STAT1, LKB1, and pAMPK expression was performed. (n) Flow cytometry analysis of cell surface PD-L1 of tumor cells from mice bearing LLC1-shLkb1 and LLC1-shCtrl tumors. (o) Tumors from mice bearing LLC1-shLkb1 and LLC1-shCtrl derived tumors were analyzed by Q-PCR for detecting CXCL9, CXCL10, CXCL11 and CCL5. (p) Representative IHC staining of CD8+ T cells and quantification of infiltrated CD8+ T cells in LLC-LV-Lkb1 tumors treated with indicated treatment (n=3 mice each group). Scale bar: 100 µm. n = 5 fields from independent tumors. Error bars represent mean ± SD. Statistical analyses were performed using unpaired t-tests. (****, P < 0.0001; ***, P < 0.001; **, P < 0.01; *, P < 0.05). (q) LLC1/LV-Ctrl or LLC1/LV-Lkb1 tumors were administered with different treatments, anti-PD-1 monotherapy or combination treatment (n=7 mice/group). Tumor size was monitored. Results are presented as mean ± SEM; * P < 0.05; two-way ANOVA.

  • Open Access

    Supplementary Table 2 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer

    by Li-Li Long, Si-Cong Ma, Ze-Qin Guo, Yan-Pei Zhang, Zhenzhen Fan, Li-Juan Liu, Li Liu, Duan-Duan Han, Meng-Xin Leng, Jian Wang, et al.

    LKB1-interacting proteins identified by LC-MS/MS analysis.

  • Open Access

    Figure S2 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer

    by Li-Li Long, Si-Cong Ma, Ze-Qin Guo, Yan-Pei Zhang, Zhenzhen Fan, Li-Juan Liu, Li Liu, Duan-Duan Han, Meng-Xin Leng, Jian Wang, et al.

    Mechanistic link between LKB1 and PARP1. (a) A bioinformatics tool (Pepsite) was utilized to predict the possibility of PARP1 docking on the di-Arg ER retention motif of LKB1 (PRR). (b) Localization of PARP1 (green) relative to LKB1 (red) in LKB1-WT A549 cells and H1299 cells. Scale bar = 20 μm. (c) Lysates from H1299 cells were subjected to IP with anti-PARP1 and anti-LKB1 antibodies and western blot analysis with the indicated antibodies. (d) IHC statistical analysis of PAR expression in LLC-shCtrl and LLC-shLkb1 tumors. n=5 fields from independent tumors. Data are represented as mean ± SD; Student's t-tests; **, P < 0.01.

  • Open Access

    Figure S5 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer

    by Li-Li Long, Si-Cong Ma, Ze-Qin Guo, Yan-Pei Zhang, Zhenzhen Fan, Li-Juan Liu, Li Liu, Duan-Duan Han, Meng-Xin Leng, Jian Wang, et al.

    Olaparib-derived dual effects sensitize LKB1-deficient tumors to anti-PD-1 immunotherapy in preclinical models. (a) Mice-bearing orthotopic lung tumors were treated with different therapies. Bioluminescent images were shown. (b) Immunofluorescence staining of PD-L1 and CD8+T cells in resected lung tumors of mice bearing orthotopic tumors (n= 6 fields from independent tumors). Scale bar, 100 μm. (c). Quantification of tumor-infiltrating CD8+ T cells in immunofluorescence staining. (d, e) IHC statistical analysis of PAR and PD-L1 expression in resected lung tumors of mice bearing orthotopic tumors (n=5 fields from independent tumors). (f) Quantification of tumor-infiltrating CD8+ T cells in IHC staining in resected lung tumors of mice bearing orthotopic tumors (n= 5 fields from independent tumors). Data are represented as mean ± SD; Student's t-tests; * P < 0.05; ** P < 0.01; ***P<0.001; ****P<0.0001; ns, not significant. (g) Mean growth curve and individual growth curves of mice treated with different therapies (n=5~7 mice/group) in the first batch. Individual mice were injected with 1 × 106 LLC1 cells and the tumor volumes were monitored for 24 days. Results are presented as mean ± SEM; ****P < 0.0001; *** P < 0.001; ** P < 0.01; * P < 0.05, two-way ANOVA.

  • Open Access

    Figure S4 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer

    by Li-Li Long, Si-Cong Ma, Ze-Qin Guo, Yan-Pei Zhang, Zhenzhen Fan, Li-Juan Liu, Li Liu, Duan-Duan Han, Meng-Xin Leng, Jian Wang, et al.

    PARP1 inhibition restores phosphorylated STAT1 from poly(ADP-ribosyl)ation and triggers synthetic lethality in LKB1-deficient cells. (a) A549 lung cancer cells were transfected with lentivirus expressing the indicated genes (LV-Ctrl, LV-LKB1-WT, and LV-LKB1-Mut) followed by treatment with olaparib (5μM) for 24 hours. The expression of pSTAT1 and PARP1 was analyzed by western blotting. (b-d) LLC1-shLkb1 and LLC1-shCtrl cells were pre-treated with olaparib (5μmol/L) for 6 hours and then stimulated with IFNγ for another 24 hours. Total pSTAT1 and STAT1 were quantified using western blot (b) and cell-surface PD-L1 was measured by flow cytometry (c). Q-PCR analysis was used to detect the expression of CXCL9 and PD-L1 (d). (e, f) The three groups of A549 cells were treated with IFNγ or IFNγ/olaparib and then refreshed the culture medium. The ratio of CD8+ T (effector cells) to A549 cells (target cell) ratio was 5:1. After 6 hours of incubation, QT-PCR analysis was used to detect the expression of indicated molecules of CD8+ T cells. (g) CD8+ T cells were treated with PBS or olaparib (5μmol/L) for 24 hours, and then the cells were collected for quantification of GZMB, PRF1, TNF, and IFNγ. CD8a was selected as the reference gene. (h) LLC-LV-Ctrl cells were treated with IFNγ/anti-PD-1 antibodies (20 μg/mL) in the absence or presence of olaparib (5 µM) or BMDCs (Tumor cells: DCs= 1:1) for 24 hours. Flow cytometry assay was used for apoptosis analysis of tumor cells. The right graph showed the quantification of tumor cell apoptosis. The data are presented as the mean ± SD of triplicate experiments. Statistical significance was determined by Student's t-test; ns, not significant; ****, P < 0.0001; ***, P < 0.001; **, P < 0.01; *, P < 0.05.